USPTO trademark

RIBOGALPLEX

AllowedUSPTOWord markClass 5Class 42

"RIBOGALPLEX" is a word mark owned by Suzhou Ribo Life Science Co., Ltd., filed at the USPTO on January 28, 2026. It has been allowed and covers classes 5 and 42.

Get this data via the API
Official USPTO record
RIBOGALPLEX trademark as filed
As filed with the USPTO
Status
Allowed
Since August 18, 2026
Filed
January 28, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99620295
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
2 classes
Ownership

Who owns RIBOGALPLEX

The owner and representative on file with the office.

Owner

Suzhou Ribo Life Science Co., Ltd.

Kunshan City, Jiangsu, China

Representative

Zhi Dong

HSML, P. C.

Goods and services

What the mark covers

The products and services RIBOGALPLEX is filed for, grouped by Nice class.

  • medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; Biological preparations for use in cell cultures for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; Pharmaceutical products for the treatment of cancer; anti-cancer preparations; Biopharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment and prevention of cancer; tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; Anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic foods and beverages adapted for medical use; depuratives for the body; pesticides; Medical dressings; Composite materials for dental and dental technical purposes

  • technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; research and development services of new pharmaceutical products; research and development in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Noa e-mailed - sou required from applicant
  2. Official gazette publication confirmation e-mailed
  3. Published for opposition
  4. Notification of notice of publication e-mailed
  5. Approved for pub - principal register
  6. Assigned to examiner
  7. New application office supplied data entered
  8. Application filing receipt mailed
  9. New application entered
FAQ

About RIBOGALPLEX

Who owns the trademark "RIBOGALPLEX"?

The USPTO trademark "RIBOGALPLEX" (application 99620295) is owned by Suzhou Ribo Life Science Co., Ltd.

What is the status of "RIBOGALPLEX"?

Its status at the USPTO is: allowed.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull RIBOGALPLEX and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b96-c16c-74fb-83f5-bc6d854af7e0
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b96-c16c-74fb-83f5-bc6d854af7e0",
  "object": "trademark",
  "mark_text": "RIBOGALPLEX",
  "status": {
    "primary": "pending",
    "stage": "allowed"
  },
  "office_code": "US",
  "application_number": "99620295",
  "filing_date": "2026-01-28",
  "nice_classes": [
    5,
    42
  ],
  "owners": [
    {
      "name": "Suzhou Ribo Life Science Co., Ltd.",
      "entity_id": null
    }
  ]
}